Biogen Reports Strong Earnings and Revenue Growth, Driving Stock Higher
Biogen (BIIB) reported strong first-quarter 2026 earnings and revenue growth, leading to a 6% stock increase despite a guidance cut. The company's revenue rose 2% year-over-year to $2.48 billion, exceeding expectations, while net income increased 19% to $529 million. The growth was driven by its 'growth products' portfolio, including Leqembi and Skyclarys.
Tickers: $BIIB
Topics: Acquisition Alzheimer's Treatment Biogen Earnings Revenue Growth